Seattle Genetics to Acquire Cascadian Therapeutics

Edward Kim  |

We discussed the merits of Cascadian Therapeutics (Nasdaq: CASC) and its therapeutic program targeting late stage breast cancer in this space in July 2017 when CASC was trading below $4.25. The price action in CASC over the past couple of weeks was pointing to a deal in the works, and the company announced today that it had agreed to be acquired by Seattle Genetics (Nasdaq: SGEN) for $10.00 per share in cash, or approximately $614 million.

Cascadian's most advanced program is in tucatinib, an oral tyrosine kinase inhibitor that is highly selective for HER2, the Human Epidermal growth factor Receptor 2 protein. In about one of every five breast cancer patients, the cancer cells have a gene mutation that makes an excess of the HER2 protein, according to the Mayo Clinic. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer and are less likely to be sensitive to hormone therapy.

HER2 is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric, and tucatinib is currently being evaluated in a randomized global pivotal trial for patients with HER2-positive metastatic breast cancer, including patients with or without brain metastases. Tucatinib has been evaluated as a single agent and in combination with both chemotherapy and other HER2-directed agents including Herceptin (trastuzumab) and Kadcyla (trastuzumab emtansine).

Cascadian Therapeutics' pipeline

Source: Cascadian Therapeutics

Other companies pursuing tyrosine kinase inhibitors

Tucatinib works by inhibiting tyrosine kinase, an important mediator of the cell signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli. If you missed the boat on Cascadian, there are numerous other companies pursuing tyrosine kinase inhibitors in their respective pipelines, including:


Please email us at content@equities.com to see our Case Studies and Testimonials.

Please click here if you would like information on our new trading platform.

Please click here if you would like to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Market Movers

Sponsored Financial Content